Dextrose Monohydrate
25 g/50mL · Injection, Solution
- Prescription only
- Active substance
- Dextrose Monohydrate
- Made by
- HF Acquisition Co LLC, DBA HealthFirst
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
At a glance
Quoted from the official label · 2024-02-22
Not necessarily this product — shortages are reported per presentation. Your pharmacy will know. · Updated 2026-09-22 FDA drug shortages
- 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.
The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour.
Full directions ↓A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.
All warnings ↓- Prescription only
- FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed
What it is for
- 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.
- The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements.
- Slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and
- avoid production of hyperglycemia.
From the official label · 2024-02-22 · DailyMed
How it works
From this product’s own US prescribing label.
When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories.
Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2024-02-22
Do not take it if
- A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.
- Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.
Quoted from the official label, section “Contraindications”.
How to take it
These directions are for this exact strength and form. Another one is different.
- For peripheral vein administration: Injection of the solution should be made slowly.
- The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour.
- About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.
- In insulin-induced hypoglycemia, intravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50% dextrose) is usually adequate.
- Repeated doses and supportive treatment may be required in severe cases.
- A specimen for blood glucose determination should be taken before injecting the dextrose.
- In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results.
- For central vein administration:
- For total parenteral nutrition 50% Dextrose Injection, USP is administered by slow intravenous infusion (a) after admixture with amino acid solutions via an indwelling catheter with the tip positioned in a large central vein, preferably the superior vena cava, or (b) after dilution with sterile water for injection.
- Dosage should be adjusted to meet individual patient requirements.
- Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
- The maximum rate of dextrose administration which does not result in glycosuria is the same as cited above.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- See CONTRAINDICATIONS .
Quoted from the official label, section “Dosage & Administration”.
Other warnings
- 50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.
- Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration.
- The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.
- The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
- Additives may be incompatible.
- Consult with pharmacist if available.
- When introducing additives, use aseptic technique, mix thoroughly and do not store.
- The solution should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.
- For central venous administration:
- Concentrated dextrose should be administered via central vein only after suitable dilution.
- Do not use unless the solution is clear and seal is intact.
- Discard unused portion.
- Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.
- Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected.
- Essential vitamins and minerals also should be provided as needed.
- To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, add insulin.
- When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextrose injection to
- avoid rebound hypoglycemia.
- Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
- Care should be exercised to ensure that the needle is well within the lumen of the vein and that extravasation does not occur.
- If thrombosis should occur during administration, the injection should be stopped and corrective measures instituted.
- Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.
- Carcinogenesis, Mutagenesis, Impairment of Fertility: Pregnancy Category C.
- Animal reproduction studies have not been conducted with dextrose.
- It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
- Dextrose should be given to a pregnant woman only if clearly needed.
- Nursing Mothers: It is not known whether this drug is excreted in human milk.
- Because many drugs are excreted in human milk, caution should be exercised when 50% Dextrose Injection, USP is administered to a nursing mother.
Quoted from the official label, section “Warnings”.
If you take too much
In an emergency, call your local emergency number or a poison control centre.
in the event of overhydration or solute overload during therapy, re-evalutate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS .
Quoted from the official label, section “Overdosage”.
Side effects
- Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness.
- Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
- If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Quoted from the official label, section “Adverse Reactions”.
What it looks like and how it is packed
- 50% Dextrose Injection, USP 25 g/50 mL (0.5 g/mL) is supplied in single-dose prefilled syringes as follows:
- NDC 51662-1584-1 50% Dextrose Injection, USP 25 g/50 mL (0.5 g/mL) HF Acquisition Co LLC, DBA HealthFirst Mukilteo, WA 98275 Syringe Assembly Directions:
- USE ASEPTIC TECHNIQUE Do not assemble until ready to use. *CAUTION:
- IMPROPER ENGAGING MAY CAUSE GLASS BREAKAGE AND SUBSEQUENT INJURY.
- Exposure of pharmaceutical products to heat should be minimized.
- Avoid excessive heat.
- Protect from freezing.
- Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Also supplied in the following manufacture supplied dosage forms:
- 50% Dextrose Injection, USP 25 g/50 mL (0.5 g/mL) is supplied in single-dose prefilled syringes as follows:
- NDC No.
- Stock No.
- Container Size Needle 76329-3302-1 3302 50 mL None One shrink wrapped package containing 10 unit cartons, each containing a Luer-Jet™ Luer-Lock Prefilled Syringe.
- Revised 01/21 6933010E © International Medication Systems, Ltd., 2021 International Medication Systems, Ltd.
- South El Monte, CA 91733, USA An Amphastar Pharmaceuticals Company Printed in USA HOW SUPPLIED
Quoted from the official label, section “How Supplied”.
What is in it
- 50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher. Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.5 mOsmol/mL (calc.) and a pH of 3.2-6.5. May contain Hydrochloric acid and/or Sodium hydroxide for pH adjustment. The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit. Dextrose, USP is chemically designated C6H12O6
- H2O (D-glucose monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following formula:
- Water for Injection, USP is chemically designated H2O. The delivery device is composed of a 50 mL glass syringe barrel with rubber stopper, and custom molded IMS injector with Luer Connector. STRUCTURE
Quoted from the official label, section “Description”.
Ingredients people check for
Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.
The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.
Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.
Every version of this medicine (9)
The same active substance, strength and kind of form, from every company that sells it — with what each label lists.
Showing 9 of 9
- Dextrose MonohydrateThis onePrescription onlyHF Acquisition Co LLC, DBA HealthFirstNo ingredient list on the stored label
- DextrosePrescription onlyHenry Schein, Inc.No ingredient list on the stored label
- DextrosePrescription onlyHF Acquisition Co LLC, DBA HealthFirstNo ingredient list on the stored label
- DextrosePrescription onlyHospira, Inc.No ingredient list on the stored label
- Dextrose MonohydratePrescription onlyInternational Medication Systems, LimitedNo ingredient list on the stored label
- DextrosePrescription onlyMedical Purchasing Solutions, LLCNo ingredient list on the stored label
- Dextrose MonohydratePrescription onlyMedical Purchasing Solutions, LLCNo ingredient list on the stored label
- DextrosePrescription onlyProPharma DistributionNo ingredient list on the stored label
- DextrosePrescription onlyREMEDYREPACK INC.No ingredient list on the stored label
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
CanadaNo exact match for this strength and form
Details
| Made by | HF Acquisition Co LLC, DBA HealthFirst |
|---|---|
| Active substance | Dextrose Monohydrate |
| Strength | 25 g/50mL |
| Form | Injection, Solution |
| Route | Intravenous |
| Packs | 1 SYRINGE in 1 CARTON / 50 mL in 1 SYRINGE · 10 POUCH in 1 CASE / 1 SYRINGE in 1 POUCH / 50 mL in 1 SYRINGE |
| NDC | 51662-1584 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Injection, Solution3 products
25 g/50mL3
25 g/50mL · 3 companies
- HF Acquisition Co LLC, DBA HealthFirst · this page
- International Medication Systems, Limited
- Medical Purchasing Solutions, LLC
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.